Stockreport

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium [Yahoo! Finance]

enVVeno Medical Corporation  (NVNO) 
PDF meaningful benefit responder rate, 75% median reduction in pain, and 87% median ulcer area reduction. The data supports the company's application for pre-market authoriz [Read more]